{"disease":{"id":"infectious-disease-of-abdomen","name":"Infectious disease of abdomen","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":52,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"mezlocillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"MEZLOCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"Interleukin-8","drug_class":"mezlocillin","quality_score":36,"revenue":null,"mechanism":""},{"drug_id":"fusidic-acid","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"gentamicin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"erythromycin-ethyl-succinate","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eryped","generic_name":"Erythromycin ethyl succinate","company_name":"Arbor Pharms Llc","drug_phase":"marketed","molecular_target":"","drug_class":"Macrolide","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"doripenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Doribax","generic_name":"DORIPENEM","company_name":"Shionogi","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":32,"revenue":null,"mechanism":""},{"drug_id":"tigecycline","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tygacil","generic_name":"TIGECYCLINE","company_name":"Fresenius Kabi","drug_phase":"marketed","molecular_target":"30S ribosomal subunit","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Tygacil works by binding to the 30S ribosomal subunit of bacteria, preventing the aminoacyl-tRNA from binding and thereby inhibiting protein synthesis."},{"drug_id":"clindamycin-phosphate","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin T","generic_name":"CLINDAMYCIN PHOSPHATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Lincosamide Antibacterial","quality_score":51,"revenue":null,"mechanism":"Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death."},{"drug_id":"cefepime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"CEFEPIME","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":59,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug."},{"drug_id":"eravacycline-dihydrochloride","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Xerava","generic_name":"ERAVACYCLINE DIHYDROCHLORIDE","company_name":"Tetraphase Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":51,"revenue":null,"mechanism":"Xerava works by binding to the bacterial ribosome, preventing the synthesis of essential proteins necessary for bacterial survival."},{"drug_id":"cefotaxime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Claforan","generic_name":"CEFOTAXIME","company_name":"Sterimax","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":30,"revenue":null,"mechanism":""},{"drug_id":"ampicillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"AMPICILLIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily M member 4","drug_class":"Penicillin-class Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"clindamycin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin","generic_name":"clindamycin","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"50S ribosomal protein L10","drug_class":"Lincosamide antibiotic","quality_score":56,"revenue":null,"mechanism":"Lincosamide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with excellent anaerobic coverage."},{"drug_id":"moxifloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avelox","generic_name":"moxifloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"Fluoroquinolone antibiotic (fourth-generation)","quality_score":57,"revenue":null,"mechanism":"Fourth-generation fluoroquinolone with the broadest spectrum, covering gram-positive, gram-negative, anaerobic, and atypical organisms."},{"drug_id":"amphotericin-b","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"sulbactam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Unasyn","generic_name":"SULBACTAM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Serine beta-lactamase-like protein LACTB, mitochondrial","drug_class":"beta Lactamase Inhibitor","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"metronidazole","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefepime-hydrochloride","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Maxipime","generic_name":"Cefepime Hydrochloride","company_name":"Baxter","drug_phase":"marketed","molecular_target":"Bacterial cell wall peptidoglycan","drug_class":"Cephalosporin","quality_score":64,"revenue":null,"mechanism":"Cefepime is a cephalosporin antibacterial drug that inhibits bacterial cell wall synthesis."},{"drug_id":"piperacillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"cefepim","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cefepim","company_name":"University Hospital Tuebingen","drug_phase":"discontinued","molecular_target":"Bacterial penicillin-binding protein","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"tygacil","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Tygacil","generic_name":"Tigecycline","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Bacterial protein synthesis","drug_class":"Tetracycline","quality_score":10,"revenue":null,"mechanism":"Tigecycline is a tetracycline class antibacterial agent."},{"drug_id":"cefamandole","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"alatrofloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"ALATROFLOXACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"alatrofloxacin","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"avelox","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Avelox","company_name":"Novartis Pharmaceuticals","drug_phase":"marketed","molecular_target":"DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"avibactam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Avycaz","generic_name":"AVIBACTAM","company_name":"Cerexa Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor [EPC]","quality_score":54,"revenue":null,"mechanism":"EMBLAVEO is an antibacterial drug."},{"drug_id":"merrem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Merrem","company_name":"National Institutes of Health Clinical Center (CC)","drug_phase":"marketed","molecular_target":"Beta-lactamase, Beta-lactamase NDM-1, Beta-lactamase class B VIM-2","drug_class":"","quality_score":23,"revenue":null,"mechanism":null},{"drug_id":"aztreonam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Azactam","generic_name":"AZTREONAM","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Monobactam Antibacterial [EPC]","quality_score":10,"revenue":null,"mechanism":"Aztreonam inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"ertapenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Invanz","generic_name":"ERTAPENEM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Penem Antibacterial","quality_score":70,"revenue":null,"mechanism":"Invanz works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"imipenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"IMIPENEM","company_name":"Merck Sharp & Dohme B.V.","drug_phase":"marketed","molecular_target":"","drug_class":"imipenem","quality_score":70,"revenue":null,"mechanism":"Primaxin works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftolozane","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zerbaxa","generic_name":"CEFTOLOZANE","company_name":"Cubist Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":"Zerbaxa works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"amikacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"ceftazidime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"cefoxitin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"meropenem","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Merrem","generic_name":"Meropenem","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"meropenem","quality_score":10,"revenue":null,"mechanism":"Meropenem works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"cefotetan","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefotan","generic_name":"CEFOTETAN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"cilastatin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Primaxin","generic_name":"CILASTATIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dipeptidase 1","drug_class":"Renal Dehydropeptidase Inhibitor","quality_score":65,"revenue":null,"mechanism":"Primaxin works by inhibiting the action of dehydropeptidase, an enzyme that breaks down certain antibiotics, thereby protecting them from degradation and allowing them to reach effective concentrations in the body."},{"drug_id":"relebactam","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Recarbrio","generic_name":"RELEBACTAM","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"","drug_class":"Renal Dehydropeptidase Inhibitor [EPC]","quality_score":34,"revenue":null,"mechanism":"Recarbrio works by inhibiting the beta-lactamase enzymes produced by certain bacteria, allowing carbapenem antibiotics to effectively target and kill the bacteria."},{"drug_id":"ticarcillin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"kanamycin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Kanacin","generic_name":"KANAMYCIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Gap junction beta-2 protein","drug_class":"Aminoglycoside Antibacterial","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"tazicef","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"norfloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cefmetazole","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zefazone","generic_name":"CEFMETAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Insulin-degrading enzyme","drug_class":"cefmetazole","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftazidim","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Infectious disease of abdomen","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":52,"totalPipeline":0},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}